Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with
pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks. Assessment of safety and
tolerability of drug combination